ATX 3 334 -0,5%  Dow 24 526 0,6%  Nasdaq 6 394 0,0%  Euro 1,1727 -0,4% 
ATX P 1 686 -0,2%  EStoxx50 3 600 0,5%  Nikkei 22 866 -0,3%  CHF 1,1635 -0,4% 
DAX 13 184 0,5%  FTSE100 7 500 0,6%  Öl 63,6 -1,8%  Gold 1 240 -0,2% 

Aimmune Therapeutics Aktie [WKN DE: A14X6J / ISIN: US00900T1079]

07.12.2017 14:00:00

Aimmune Therapeutics to Participate in the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference on December 14


Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that Chief Financial Officer Eric Bjerkholt will participate in a fireside chat at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference on Thursday, December 14, 2017, in New York City.

A live webcast of the presentation will be accessible on the Events page under the Investor Relations section of the Aimmune website at www.aimmune.com. A replay of the webcast will be available for at least 30 days following the webcast.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical company developing treatments for life-threatening food allergies. The company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to achieve meaningful levels of protection by desensitizing patients with defined, precise amounts of key allergens. Aimmune’s first investigational biologic product using CODIT™, AR101 for the treatment of peanut allergy, has received the FDA’s Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4-17 years of age and is currently being evaluated in Phase 3 clinical trials. For more information, please see www.aimmune.com.

This press release concerns a product that is under clinical investigation and that has not yet been approved for marketing by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). It is currently limited to investigational use, and no representation is made as to its safety or effectiveness for the purposes for which it is being investigated.

Analysen zu Aimmune Therapeutics Inc

mehr Analysen
  • Alle
  • Buy
  • Hold
  • Sell
01.03.16 Aimmune Therapeutics Outperform Wedbush Morgan Securities Inc.

Eintrag hinzufügen

Aktien in diesem Artikel

Nachrichten

  • Nachrichten zu Aktien
  • Alle Nachrichten
pagehit